Partial epigenetic reprogramming of retinal pigment cells in age-related degeneration, dysfunction, and injury
Partial epigenetic reprogramming of retinal pigment cells in age-related degeneration, dysfunction, and injury
批准号:
10644270
负责人:
Zhengping Hu
金额:
$11.4万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-01 至 2025-06-30
关键词:
AdultAgeAge related macular degenerationAgingAtrophicBlindnessCell AgingCell DeathCell ReprogrammingCell physiologyCellsCellular MorphologyCellular StressCholesterolComplementComplement ActivationCrush InjuryDNADNA MethylationDataDepositionDevelopmentDietDoxycyclineDrynessElderlyElectrophysiology (science)ElectroretinographyEpigenetic ProcessExudative age-related macular degenerationEye diseasesFatty acid glycerol estersFunctional disorderGene DeliveryGene ModifiedGlaucomaHeterozygoteHumanIn VitroInjuryInvestigationKnowledgeMediatingMentorsModelingModificationMolecularMorphologyMusNeural RetinaNitrogenNonexudative age-related macular degenerationOptic NerveOxidative StressOxygenPathologicPathologyPathway interactionsPatientsPatternPhasePhotoreceptorsPlayPopulationProcessRegenerative capacityReportingResearch PersonnelResistanceRetinaRetinal DegenerationRetinal DiseasesRetinal Ganglion CellsRetinal PigmentsRiskRisk FactorsRoleSafetySerumSignal PathwaySiteStructure of retinal pigment epitheliumTestingTherapeuticTobaccoTobacco smoking behaviorTrainingTransmission Electron MicroscopyVisionWorkage relatedagedaxon regenerationbevacizumabcareercell injurycigarette smokingcomparativeepigenomeepithelial injuryhigh riskimprovedin vivoin vivo Modelin vivo regenerationinduced pluripotent stem cellinsightjuvenile animalmethylation patternmouse modelneovascularnovel therapeutic interventionoxidized low density lipoproteinpluripotencypreventprogramsresponsesenescenceskillssodium iodatestem cell differentiationtranscriptome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Retinal pigment epithelial (RPE) cell dysfunction and damage are hallmarks of age-related macular
degeneration (AMD), the leading cause of blindness in the elderly. While anti-VEGF has revolutionized the
management of wet or exudative AMD, there is currently no treatment available for non-exudative AMD. Aging
is the major risk factor for RPE degeneration and the development of AMD. During aging, epigenetic changes
disrupt "youthful" DNA methylation patterns, leading to cellular dysfunction and senescence. Partial epigenetic
reprogramming via ectopic induction of three Yamanaka factors, Oct4, Sox2, Klf4 (OSK), in retinal ganglion
cells was recently reported to reprogram and reverse epigenetic age, leading to vision improvement in aged
mice as well as in a mouse glaucoma model. I propose to test the hypothesis that partial epigenetic
reprogramming can rescue age-related RPE cell degeneration and function in vivo, prevent RPE cell injury
induced by a range of insults in vitro, and inhibit the formation of AMD-like pathologies in a mouse model with
the following aims. (i) To determine whether OSK-mediated epigenetic reprogramming can restore RPE
morphology and function in aged mice, I will examine the visual function and RPE morphology in aged mice
with and without OSK induction by optomotor, ERG, RPE flatmount, and transmission electron microscopy. In
addition, I will compare the transcriptomes and epigenomes of RPE from aged mice with and without OSK
induction to assess the effect of OSK expression. (ii) To test the ability of OSK-induction in rescuing primary
human RPE cells from morphologic and functional changes, as well as cell death following various AMD-
associated insults in vitro, including oxidative stress, ox-LDL, and cigarette smoking extract. I will also examine
the effect of OSK-induction in iPSC-RPE cells derived from high-risk and low-risk donors with AMD. (iii)
Examine the role of OSK induction in NaIO3-treated mice, a short-term injury model that induces regional RPE
atrophy, and in RPE specific aged Cfh heterozygous (Cfh+/-) mice fed with a high fat, high cholesterol diet,
which have pathological changes mimicking early dry AMD. The results of these investigations will reveal the
efficacy and viability of epigenetic reprogramming as a therapeutic strategy for RPE regeneration in vivo. My
mentoring panel and the proposed training plan will equip me with new knowledge and skills to study age-
related retinal diseases and will catalyze my transition to a career as an independent investigator.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: